XELOX和FOLFOX化疗方案对中晚期胃癌患者生活质量的影响及毒副反应  

Effects of XELOX and FOLFOX chemotherapy regimens on quality of life and toxic side effects in patients with advanced gastric cancer

作　　者：李红志[1] 邵珊珊 邵卫玲 陈德虎 LI Hong-zhi;SHAO Shan-shan;SHAO Wei-ling;CHEN De-hu(Department of Oncology,Taizhou People’s Hospital,Taizhou 225300,Jiangsu,China;Department of General Surgery,Taizhou People’s Hospital,Taizhou 225300,Jiangsu,China)

机构地区：[1]泰州市人民医院肿瘤科,江苏泰州225300 [2]泰州市人民医院普外科,江苏泰州225300

出　　处：《川北医学院学报》2019年第5期578-581,共4页Journal of North Sichuan Medical College

基　　金：江苏省泰州市科技支撑计划(社会发展)项目(TS201732)

摘　　要：目的:探讨XELOX和FOLFOX化疗方案治疗中晚期胃癌患者的效果和安全性。方法:采用单盲随机分组法,将120例中晚期胃癌患者分为对照组和观察组,每组各60例。对照组采用亚叶酸钙(CF)+氟尿嘧啶(5-FU)+奥沙利铂(L-OHP)的FOLFOX化疗方案,观察组采用卡培他滨(Cap)+奥沙利铂(L-OHP)的XELOX化疗方案。采用实体瘤评价标准(RECIST)和毒性评价标准(CTC)评估两组实体瘤疗效和毒副反应情况。结合2年随访,统计两组预后生存情况,采用生活质量量表(QLQ-STO22)评估两组患者生活质量。结果:两组胃癌患者均成功完成化疗,无化疗相关性死亡。观察组肿瘤缓解有效率(RR)、疾病控制率(DCR)与对照组比较(51.67%vs.46.67%、86.67%vs.83.33%),差异均无统计学意义(P>0.05);两组毒副反应程度I^II度,观察组恶心呕吐、腹泻发生率低于对照组,但手足综合征、口腔黏膜炎发生率高于对照组,差异均有统计学意义(P<0.05);两组随访1年、2年生存率和QLQ-STO22量表9项评分比较,差异均无统计学意义(P>0.05)。结论:XELOX和FOLFOX治疗中晚期胃癌的临床疗效和对患者生活质量的影响效果相当,毒副反应略有不同,但均可耐受。Objective:To investigate the efficacy and safety of XELOX and FOLFOX chemotherapy regimens in the treatment of advanced gastric cancer patients.Methods:120 patients with advanced gastric cancer were divided into control group and observation group by single blind random grouping method,60 cases in each group/The control group was treated with FOLFOX regimen of calcium folinate(CF)+fluorouracil(5-FU)+oxaliplatin(L-OHP),while the observation group was treated with XELOX regimen of capeci-tabine(Cap)+oxaliplatin(L-OHP).The efficacy and toxic side effects of solid tumors were evaluated by RECIST and CTC.Combined with two years follow-up,the prognosis and survival of the two groups were counted,and the quality of life of the two groups was assessed by QLQ-STO22.Results:Chemotherapy was successfully completed in both groups without chemotherapy-related death.There was no significant difference in RR and DCR between the observation group and the control group(51.67%vs.46.67%,86.67%vs.83.33%),there was no significant difference(P>0.05).The degree of toxic side effects was I-II in the two groups.The incidence of nausea,vomiting and diarrhea in the observation group was lower than that in the control group,but the incidence of hand-foot syndrome and oral mucositis in the observation group was higher than that in the control group(P<0.05).There was no significant difference in 1-year,2-year survival rate and 9 items of QLQ-STO2 scale between the two groups(P>0.05).Conclusion:The clinical efficacy of XELOX and FOLFOX in the treatment of advanced gastric cancer is similar to that of FOLFOX in the quality of life.Although the toxicity and side effects are slightly different,they are tolerable.

关 键 词：胃癌 中晚期 XELOX方案 FOLFOX方案 生活质量 毒副反应 

分 类 号：R735.2[医药卫生—肿瘤]